Qube Research & Technologies (QRT)’s Climb Bio CLYM Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.48M	Buy	266,649 +162,432	+156%	+$1.68M	﹤0.01%	1820
2026 Q1	$714K	Buy	104,217 +69,621	+201%	+$402K	﹤0.01%	2623
2025 Q4	$138K	Sell	34,596 -2,006	-5%	-$4.82K	﹤0.01%	3132
2025 Q3	$73.6K	Buy	36,602 +2,292	+7%	+$4.26K	﹤0.01%	3115
2025 Q2	$42.5K	Buy	+34,310	New	+$42.7K	﹤0.01%	3182
2024 Q2	–	Sell	-981	Closed	-$2.69K	–	4882
2024 Q1	$2.69K	Hold	981	–	–	﹤0.01%	3968
2023 Q4	$2.63K	Hold	981	–	–	﹤0.01%	3798
2023 Q3	$2.59K	Buy	+981	New	+$2.67K	﹤0.01%	3545
2022 Q2	–	Sell	-15,874	Closed	-$133K	–	3230
2022 Q1	$133K	Buy	+15,874	New	+$148K	﹤0.01%	2026

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Qube Research & Technologies (QRT)'s CLYM Position: Q2 2026 in Review

Qube Research & Technologies (QRT) increased its Climb Bio (CLYM) stake by 156% in Q2 2026, buying an estimated $1.68M and bringing the position to 266,649 shares worth $3.48M. The position accounts for ﹤0.01% of the portfolio, ranked #1820.

Qube Research & Technologies (QRT) first reported a position in CLYM in Q1 2022 and has held it in 9 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

Qube Research & Technologies (QRT) held 266,649 shares of Climb Bio worth $3.48M as of Q2 2026.
Qube Research & Technologies (QRT) bought 162,432 Climb Bio shares in Q2 2026, an estimated $1.68M.
Climb Bio made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #1820 holding.
Qube Research & Technologies (QRT) first reported a position in Climb Bio in Q1 2022 and has held it in 9 quarters since.
109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.